Brief: Prometheus Biosciences Initiates Third Phase 2 Study Of PRA023 For Systemic Sclerosis-Associated Interstitial Lung Disease
30/03/2022 13:51
March 30 (Reuters) - Prometheus Biosciences Inc RXDX.O :
* PROMETHEUS BIOSCIENCES INITIATES THIRD PHASE 2 STUDY OF
PRA023
FOR SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
(SSC-ILD)
* PROMETHEUS BIOSCIENCES INC- ATHENA-SSC-ILD PHASE 2 TOPLINE
RESULTS EXPECTED FIRST-HALF 2024
Source text for Eikon: ID:nGNXbV3jSF
Further company coverage: RXDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prometheus Biosciences
See all newsBrief: Prometheus Biosciences - Completed Merger Of Splash Merger Sub, Unit Of Merck & Co
Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
William Blair sees FTC suit on Amgen-Horizon deal weighing on biotech M&A sentiment
FTC scrutiny to block Amgen-Horizon deal drags down Seagen, Prometheus
Brief: Prometheus Biosciences Reports First Quarter 2023 Financial Results